Interleukin-17A as a Key Mediator and Therapeutic Target in Rheumatoid Arthritis: Current Evidence and Future Directions
Molecules · 19.11.2026 · 31 (22) · 4198
DOI: 10.3390/molecules31224198 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 19.11.2026. Verfasst von Waqar Ahmad und 3 weiteren Autor:innen. Die Arbeit nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Research, Development and Youth of the Slovak Republic.
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent synovitis, cartilage damage and bone degradation. Interleukin-17A (IL-17A) is a cytokine secreted primarily by T helper 17 (Th17) cells and also by CD8+ T (Tc17) cells, γδ T cells, invariant natural killer T cells, mucosal-associated invariant T cells, and group 3 innate lymphoid cells. IL-17A has been implicated in the etiology of RA, both by the association of immunological activation with synovial inflammation and structural joint damage. IL-17A acts on synovial fibroblasts and a range of immune and stromal cells together with inflammatory cytokines, especially tumor necrosis factor-α (TNF-α), to induce the production of cytokines and chemokines, matrix breakdown and Receptor activator of nuclear factor-κB ligand (RANKL)-dependent osteoclastogenesis in RA. IL-17A has been shown to be involved in synovitis and joint destruction in experimental arthritic models. Despite a strong molecular and preclinical rationale, clinical studies of IL-17-targeting therapies in RA have demonstrated uneven and generally limited efficacy. This discrepancy may reflect the molecular and cellular heterogeneity of RA, redundancy of cytokines, differences in disease progression and tissue environment, and the lack of validated biomarkers for IL17A-dependent disease. This review critically examines the signaling of IL-17A, its pathogenic and structural roles in RA, evidence from experimental arthritis models, and the clinical outcomes and limitations of IL-17-targeted therapies. Emerging approaches, including biomarker-guided patient stratification, single-cell and spatial profiling, multi-omics, broader cytokine targeting, and modulation of immune system and metabolic processes and gutjoint pathways, are also discussed. We also discuss current studies which suggest the future clinical relevance of IL-17A in patients with RA IL-17A is a main and therapeutically targetable inflammatory mechanism.
Förderung
- Ministry of Education, Research, Development and Youth of the Slovak Republic
Zitieren
APA
Ahmad, W., Umar, M., Khan, M. A., & Bauerová, K. (2026). Interleukin-17A as a Key Mediator and Therapeutic Target in Rheumatoid Arthritis: Current Evidence and Future Directions. Molecules, 31(22), 4198. https://doi.org/10.3390/molecules31224198
Vancouver
Ahmad W, Umar M, Khan MA, Bauerová K. Interleukin-17A as a Key Mediator and Therapeutic Target in Rheumatoid Arthritis: Current Evidence and Future Directions. Molecules. 2026;31(22):4198. doi:10.3390/molecules31224198
BibTeX
@article{Ahmad2026,
author = {Ahmad, Waqar and Umar, Mohammad and Khan, Muhammad Adil and Bauerová, Katarína},
title = {Interleukin-17A as a Key Mediator and Therapeutic Target in Rheumatoid Arthritis: Current Evidence and Future Directions},
journal = {Molecules},
year = {2026},
volume = {31},
number = {22},
pages = {4198},
doi = {10.3390/molecules31224198}
}
EUVIMED